Equities analysts predict that Illumina (NASDAQ:ILMN) will report $743.01 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Illumina’s earnings, with the highest sales estimate coming in at $746.00 million and the lowest estimate coming in at $740.00 million. Illumina posted sales of $598.00 million during the same quarter last year, which suggests a positive year over year growth rate of 24.2%. The business is expected to report its next quarterly earnings results after the market closes on Tuesday, April 24th.
According to Zacks, analysts expect that Illumina will report full-year sales of $3.14 billion for the current fiscal year, with estimates ranging from $3.12 billion to $3.19 billion. For the next year, analysts expect that the firm will post sales of $3.50 billion per share, with estimates ranging from $3.42 billion to $3.66 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Illumina.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.22. Illumina had a net margin of 26.56% and a return on equity of 21.71%. The business had revenue of $778.00 million during the quarter, compared to the consensus estimate of $752.04 million. During the same quarter last year, the firm earned $0.85 earnings per share. The business’s revenue for the quarter was up 25.7% on a year-over-year basis.
A number of equities analysts have weighed in on ILMN shares. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. Piper Jaffray reaffirmed a “buy” rating and set a $269.00 target price on shares of Illumina in a research note on Tuesday, January 9th. Deutsche Bank set a $275.00 target price on shares of Illumina and gave the company a “buy” rating in a research note on Tuesday, January 16th. Canaccord Genuity reaffirmed a “buy” rating and set a $265.00 target price (up previously from $255.00) on shares of Illumina in a research note on Wednesday, January 31st. Finally, Citigroup raised shares of Illumina from a “neutral” rating to a “buy” rating and raised their target price for the company from $260.00 to $275.00 in a research note on Monday, February 5th. One analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $243.03.
In related news, EVP Marc Stapley sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $242.33, for a total value of $484,660.00. Following the sale, the executive vice president now owns 29,815 shares in the company, valued at $7,225,068.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $244.18, for a total transaction of $305,225.00. Following the completion of the sale, the director now owns 8,588 shares in the company, valued at approximately $2,097,017.84. The disclosure for this sale can be found here. Insiders sold 20,008 shares of company stock worth $4,614,735 in the last 90 days. 0.54% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently modified their holdings of ILMN. Jackson Square Partners LLC boosted its holdings in Illumina by 263.0% in the fourth quarter. Jackson Square Partners LLC now owns 1,034,454 shares of the life sciences company’s stock worth $226,017,000 after purchasing an additional 749,468 shares during the last quarter. Jennison Associates LLC boosted its holdings in Illumina by 8.8% in the fourth quarter. Jennison Associates LLC now owns 4,412,621 shares of the life sciences company’s stock worth $964,114,000 after purchasing an additional 355,200 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Illumina by 371.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 212,160 shares of the life sciences company’s stock worth $46,355,000 after purchasing an additional 167,206 shares during the last quarter. Carillon Tower Advisers Inc. purchased a new stake in Illumina in the fourth quarter worth approximately $33,752,000. Finally, Guggenheim Capital LLC boosted its holdings in Illumina by 41.5% in the fourth quarter. Guggenheim Capital LLC now owns 421,361 shares of the life sciences company’s stock worth $92,065,000 after purchasing an additional 123,555 shares during the last quarter. Institutional investors own 91.68% of the company’s stock.
Shares of NASDAQ ILMN traded up $3.29 on Tuesday, reaching $248.48. 899,790 shares of the company’s stock traded hands, compared to its average volume of 870,786. Illumina has a 12 month low of $167.98 and a 12 month high of $256.64. The company has a market capitalization of $35,430.26, a price-to-earnings ratio of 62.12, a P/E/G ratio of 3.22 and a beta of 0.89. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.55 and a current ratio of 3.99.
ILLEGAL ACTIVITY WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/18/zacks-brokerages-anticipate-illumina-ilmn-will-post-quarterly-sales-of-743-01-million.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Get a free copy of the Zacks research report on Illumina (ILMN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.